Achillion shares should be bought on any weakness, says JMP Securities After Achillion announced a financing deal that JMP Securities believes may cause the stock to retreat, the firm thinks the company is poised to report "transformative data" this year. The firm thinks the company's HCV treatments have no safety risks, and it reiterates a $15 price target and Outperform rating on the shares.
Achillion initiated with an Underweight at Barclays Barclays started shares of Achillion with an Underweight rating and $8 price target citing the company's lateness to the hepatitis C market as well as competition in the space.
Achillion March calls active on renewed takeover chatter Achillion March 14 and April 15 calls are active on total call volume of 1,600 contracts (100 puts) on renewed takeover chatter. February weekly call option implied volatility is at 82, March and April is at 79, June is at 81; compared to its 10-week average of 81 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.